Patient and disease characteristics
| Characteristic . | FHCRC patients, n = 177 . | MDACC patients, n = 67 . |
|---|---|---|
| Median age at transplantation, y (range) | 41 (19-75) | 39 (19-67) |
| Median interval from diagnosis to HCT, mo | 4.8 | 5.1 |
| Conditioning regimens, % | ||
| Myeloablative, TBI-based | 45 | 43 |
| Myeloablative, non–TBI-based | 44 | 24 |
| Reduced-intensity* | 2 | 22 |
| Nonmyeloablative† | 10 | 10 |
| Postgrafting immunosuppression, % | ||
| CSP + MTX | 78 | 22 |
| Tacrolimus + MTX | 2 | 61 |
| CSP + MMF | 9 | 0 |
| Other | 11 | 17 |
| Hematopoietic cell source, % | ||
| G-PBMCs | 35 | 42 |
| Marrow | 65 | 58 |
| Donor type, % | ||
| HLA-matched sibling | 68 | 78 |
| HLA-mismatched related | 4 | 7 |
| HLA-matched unrelated | 22 | 15 |
| HLA-allele–mismatched unrelated | 3 | 0 |
| HLA-antigen–mismatched unrelated | 3 | 0 |
| Patient CMV serostatus, % | ||
| Negative | 45 | 32 |
| Positive | 55 | 68 |
| Cytogenetic risks,%‡ | ||
| Favorable | 3 | 3 |
| Intermediate | 82 | 61 |
| Unfavorable | 15 | 36 |
| Characteristic . | FHCRC patients, n = 177 . | MDACC patients, n = 67 . |
|---|---|---|
| Median age at transplantation, y (range) | 41 (19-75) | 39 (19-67) |
| Median interval from diagnosis to HCT, mo | 4.8 | 5.1 |
| Conditioning regimens, % | ||
| Myeloablative, TBI-based | 45 | 43 |
| Myeloablative, non–TBI-based | 44 | 24 |
| Reduced-intensity* | 2 | 22 |
| Nonmyeloablative† | 10 | 10 |
| Postgrafting immunosuppression, % | ||
| CSP + MTX | 78 | 22 |
| Tacrolimus + MTX | 2 | 61 |
| CSP + MMF | 9 | 0 |
| Other | 11 | 17 |
| Hematopoietic cell source, % | ||
| G-PBMCs | 35 | 42 |
| Marrow | 65 | 58 |
| Donor type, % | ||
| HLA-matched sibling | 68 | 78 |
| HLA-mismatched related | 4 | 7 |
| HLA-matched unrelated | 22 | 15 |
| HLA-allele–mismatched unrelated | 3 | 0 |
| HLA-antigen–mismatched unrelated | 3 | 0 |
| Patient CMV serostatus, % | ||
| Negative | 45 | 32 |
| Positive | 55 | 68 |
| Cytogenetic risks,%‡ | ||
| Favorable | 3 | 3 |
| Intermediate | 82 | 61 |
| Unfavorable | 15 | 36 |
HCT indicates hematopoietic cell transplantation; TBI, total body irradiation; CSP, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; G-PBMC, granulocyte colony-stimulating factor–peripheral blood mononuclear cells; HLA, human leukocyte antigen; and CMV, cytomegalovirus.
Reduced-intensity conditioning regimens included fludarabine plus busulfan or melphalan.
Nonmyeloablative regimens included 2 Gy TBI plus or minus fludarabine or fludarabine/Ara-C/idarubicin.
Cytogenetic risks were assessed and broken down into 3 risk groups: favorable, intermediate, and unfavorable, according to the criteria of the Southwest Oncology Group (SWOG)/Eastern Cooperative Oncology Group.3